These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18450771)

  • 1. Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation.
    Christesen HB; Tribble ND; Molven A; Siddiqui J; Sandal T; Brusgaard K; Ellard S; Njølstad PR; Alm J; Brock Jacobsen B; Hussain K; Gloyn AL
    Eur J Endocrinol; 2008 Jul; 159(1):27-34. PubMed ID: 18450771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational analysis of ABCC8, KCNJ11, GLUD1, HNF4A and GCK genes in 30 Chinese patients with congenital hyperinsulinism.
    Sang Y; Xu Z; Liu M; Yan J; Wu Y; Zhu C; Ni G
    Endocr J; 2014; 61(9):901-10. PubMed ID: 25008049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity in phenotype of hyperinsulinism caused by activating glucokinase mutations: a novel mutation and its functional characterization.
    Martínez R; Gutierrez-Nogués Á; Fernández-Ramos C; Velayos T; Vela A; ; Navas MÁ; Castaño L
    Clin Endocrinol (Oxf); 2017 Jun; 86(6):778-783. PubMed ID: 28247534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A report of 2 new cases of MODY2 and review of the literature: implications in the search for type 2 diabetes drugs.
    Shammas C; Neocleous V; Phelan MM; Lian LY; Skordis N; Phylactou LA
    Metabolism; 2013 Nov; 62(11):1535-42. PubMed ID: 23890519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic Characterization of Congenital Hyperinsulinism Due to Novel Activating Glucokinase Mutations.
    Li C; Juliana CA; Yuan Y; Li M; Lu M; Chen P; Boodhansingh KE; Doliba NM; Bhatti TR; Adzick NS; Stanley CA; De León DD
    Diabetes; 2023 Dec; 72(12):1809-1819. PubMed ID: 37725835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Incidence of Heterozygous ABCC8 and HNF1A Mutations in Czech Patients With Congenital Hyperinsulinism.
    Rozenkova K; Malikova J; Nessa A; Dusatkova L; Bjørkhaug L; Obermannova B; Dusatkova P; Kytnarova J; Aukrust I; Najmi LA; Rypackova B; Sumnik Z; Lebl J; Njølstad PR; Hussain K; Pruhova S
    J Clin Endocrinol Metab; 2015 Dec; 100(12):E1540-9. PubMed ID: 26431509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism.
    Kapoor RR; Flanagan SE; Arya VB; Shield JP; Ellard S; Hussain K
    Eur J Endocrinol; 2013 Apr; 168(4):557-64. PubMed ID: 23345197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations.
    Gloyn AL; Noordam K; Willemsen MA; Ellard S; Lam WW; Campbell IW; Midgley P; Shiota C; Buettger C; Magnuson MA; Matschinsky FM; Hattersley AT
    Diabetes; 2003 Sep; 52(9):2433-40. PubMed ID: 12941786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy.
    Wabitsch M; Lahr G; Van de Bunt M; Marchant C; Lindner M; von Puttkamer J; Fenneberg A; Debatin KM; Klein R; Ellard S; Clark A; Gloyn AL
    Diabet Med; 2007 Dec; 24(12):1393-9. PubMed ID: 17976205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Management and Gene Mutation Analysis of Children with Congenital Hyperinsulinism in South China.
    Xu A; Cheng J; Sheng H; Wen Z; Lin Y; Zhou Z; Zeng C; Shao Y; Li C; Liu L; Li X
    J Clin Res Pediatr Endocrinol; 2019 Nov; 11(4):400-409. PubMed ID: 31208162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conservatively treated Congenital Hyperinsulinism (CHI) due to K-ATP channel gene mutations: reducing severity over time.
    Salomon-Estebanez M; Flanagan SE; Ellard S; Rigby L; Bowden L; Mohamed Z; Nicholson J; Skae M; Hall C; Craigie R; Padidela R; Murphy N; Randell T; Cosgrove KE; Dunne MJ; Banerjee I
    Orphanet J Rare Dis; 2016 Dec; 11(1):163. PubMed ID: 27908292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia.
    Osbak KK; Colclough K; Saint-Martin C; Beer NL; Bellanné-Chantelot C; Ellard S; Gloyn AL
    Hum Mutat; 2009 Nov; 30(11):1512-26. PubMed ID: 19790256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial adult onset hyperinsulinism due to an activating glucokinase mutation: implications for pharmacological glucokinase activation.
    Challis BG; Harris J; Sleigh A; Isaac I; Orme SM; Seevaratnam N; Dhatariya K; Simpson HL; Semple RK
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):855-61. PubMed ID: 24890200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into the structure and regulation of glucokinase from a novel mutation (V62M), which causes maturity-onset diabetes of the young.
    Gloyn AL; Odili S; Zelent D; Buettger C; Castleden HA; Steele AM; Stride A; Shiota C; Magnuson MA; Lorini R; d'Annunzio G; Stanley CA; Kwagh J; van Schaftingen E; Veiga-da-Cunha M; Barbetti F; Dunten P; Han Y; Grimsby J; Taub R; Ellard S; Hattersley AT; Matschinsky FM
    J Biol Chem; 2005 Apr; 280(14):14105-13. PubMed ID: 15677479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a novel site regulating glucokinase activity following characterization of a new mutation causing hyperinsulinemic hypoglycemia in humans.
    Beer NL; van de Bunt M; Colclough K; Lukacs C; Arundel P; Chik CL; Grimsby J; Ellard S; Gloyn AL
    J Biol Chem; 2011 May; 286(21):19118-26. PubMed ID: 21454522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-insulinoma persistent hyperinsulinaemic hypoglycaemia caused by an activating glucokinase mutation: hypoglycaemia unawareness and attacks.
    Christesen HB; Brusgaard K; Beck Nielsen H; Brock Jacobsen B
    Clin Endocrinol (Oxf); 2008 May; 68(5):747-55. PubMed ID: 18208578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene.
    Barbetti F; Cobo-Vuilleumier N; Dionisi-Vici C; Toni S; Ciampalini P; Massa O; Rodriguez-Bada P; Colombo C; Lenzi L; Garcia-Gimeno MA; Bermudez-Silva FJ; Rodriguez de Fonseca F; Banin P; Aledo JC; Baixeras E; Sanz P; Cuesta-Muñoz AL
    Mol Endocrinol; 2009 Dec; 23(12):1983-9. PubMed ID: 19884385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity.
    García-Herrero CM; Galán M; Vincent O; Flández B; Gargallo M; Delgado-Alvarez E; Blázquez E; Navas MA
    Diabetologia; 2007 Feb; 50(2):325-33. PubMed ID: 17186219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy.
    Gloyn AL
    Hum Mutat; 2003 Nov; 22(5):353-62. PubMed ID: 14517946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Congenital hyperinsulinism in the north-east Netherlands. Clinical features and DNA diagnostics in 22 children].
    Verheul JC; Ris-Stalpers C; Bikker H; Bakker-van Waarde WM; Noordam C
    Ned Tijdschr Geneeskd; 2011; 155(32):A3343. PubMed ID: 21835061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.